Endothelin receptor antagonists.

Abstract

Endothelin receptor antagonists (ERAs) have been developed to block the effects of endothelin-1 (ET-1) in a variety of cardiovascular conditions. ET-1 is a powerful vasoconstrictor with mitogenic or co-mitogenic properties, which acts through the stimulation of 2 subtypes of receptors [endothelin receptor subtype A (ETA) and endothelin receptor subtype B (ETB) receptors]. Endogenous ET-1 is involved in a variety of conditions including systemic and pulmonary hypertension (PH), congestive heart failure (CHF), vascular remodeling (restenosis, atherosclerosis), renal failure, cancer, and cerebrovascular disease. The first dual ETA/ETB receptor blocker, bosentan, has already been approved by the Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH). Trials of endothelin receptor antagonists in heart failure have been completed with mixed results so far. Studies are ongoing on the effects of selective ETA antagonists or dual ETA/ETB antagonists in lung fibrosis, cancer, and subarachnoid hemorrhage. While non-peptidic ET-1 receptor antagonists suitable for oral intake with excellent bioavailability have become available, proven efficacy is limited to pulmonary hypertension, but it is possible that these agents might find a place in the treatment of several cardiovascular and non-cardiovascular diseases in the coming future.

• Authors: Sophie Motte, Kathleen McEntee, Robert Naeije
• Journal: Pharmacology & therapeutics (Pharmacol Ther) Vol. 110 Issue 3 Pg. 386-414 (Jun 2006) ISSN: 0163-7258 [Print] England
• PMID: 16219361 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antihypertensive Agents
• Endothelin Receptor Antagonists

Topics

• Animals
• Antihypertensive Agents (therapeutic use)
• Endothelin Receptor Antagonists
• Heart Failure (drug therapy, etiology, metabolism)
• Humans
• Hypertension, Pulmonary (drug therapy, etiology, metabolism)